NCT00327327View on ClinicalTrials.gov

Safety Study of Imexon Plus Gemcitabine in Untreated Pancreatic Adenocarcinoma

PHASE1CompletedINTERVENTIONAL
Enrollment

105

Participants

Timeline

Start Date

February 29, 2004

Primary Completion Date

October 31, 2009

Study Completion Date

October 31, 2009

Conditions
Pancreatic Adenocarcinoma
Interventions
DRUG

imexon

30-60 minutes IV, days 1,8,15 every 28 days

DRUG

gemcitabine

30 minutes IV, days 1,8,15 every 28 days

Trial Locations (9)

12208

US Oncology Albany, New York Oncology, Albany

19111

Fox Chase Cancer Ctr., Philadelphia

23502

US Oncology, Virginia Oncology Assoc, Norfolk

34761

US Oncology Orlando, Cancer Centers of FL, Ocoee

45409

US Oncology Kettering, Kettering

46227

US Oncology Indiana, Indianapolis

48109

Univ of Michigan, Ann Arbor

85715

Arizona Clinical Research Center, Tucson

98684

US Oncology Northwest, Northwest Cancer Specialists, Vancouver

Sponsors
All Listed Sponsors
lead

AmpliMed Corporation

INDUSTRY